middle.news
Dimerix’s DMX-200 Secures Orphan Drug Status in Japan, Boosting Rare Kidney Disease Hope
8:47am on Tuesday 30th of September, 2025 AEST
•
Healthcare
Read Story
Dimerix’s DMX-200 Secures Orphan Drug Status in Japan, Boosting Rare Kidney Disease Hope
8:47am on Tuesday 30th of September, 2025 AEST
Key Points
DMX-200 receives Orphan Drug Designation from Japanese Ministry of Health
Designation grants 10-year market exclusivity and pricing premiums in Japan
ACTION3 Phase 3 trial actively recruiting FSGS patients in Japan and globally
FUSO Pharmaceutical Industries holds exclusive development and commercialization rights in Japan
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE